Diselenide Covalent Allosteric Inhibitors of Glutaminase with Strong
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
13 Jul 2023
13 Jul 2023
Historique:
received:
03
11
2022
accepted:
28
04
2023
pmc-release:
13
07
2024
medline:
19
7
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
epublish
Résumé
Allosteric glutaminase inhibitors demonstrate inhibition of glutamine-dependent cancer cells with low general drug toxicity, but have issues with efficacy
Identifiants
pubmed: 37465295
doi: 10.1021/acsmedchemlett.2c00470
pmc: PMC10351061
doi:
Types de publication
Journal Article
Langues
eng
Pagination
920-928Informations de copyright
© 2023 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Mol Cancer Ther. 2014 Apr;13(4):890-901
pubmed: 24523301
J Med Chem. 2019 Jan 10;62(1):46-59
pubmed: 29969024
J Med Chem. 2021 Apr 22;64(8):4588-4611
pubmed: 33792311
Int J Biol Macromol. 2014 Mar;64:276-80
pubmed: 24315949
Free Radic Biol Med. 2018 Nov 1;127:238-247
pubmed: 29807162
J Med Chem. 2019 Jan 24;62(2):589-603
pubmed: 30543285
Nat Rev Cancer. 2016 Oct;16(10):619-34
pubmed: 27492215
Curr Opin Chem Biol. 2017 Aug;39:54-63
pubmed: 28609675
RSC Chem Biol. 2021 Aug 21;2(6):1669-1681
pubmed: 34977582
Acc Chem Res. 2010 Nov 16;43(11):1408-19
pubmed: 20690615
Bioorg Med Chem Lett. 2020 Jun 1;30(11):127134
pubmed: 32253062
Oncogene. 2022 Feb;41(8):1140-1154
pubmed: 35046532
Onco Targets Ther. 2016 Jun 08;9:3433-41
pubmed: 27354815
J Med Chem. 2020 Nov 12;63(21):12957-12977
pubmed: 33118821
PLoS One. 2017 Sep 26;12(9):e0185092
pubmed: 28950000
Future Med Chem. 2017 Jan;9(2):223-243
pubmed: 28111979
ACS Pharmacol Transl Sci. 2019 Jan 11;2(1):18-30
pubmed: 32219214